Record net profit and EPS were achieved on the back of all-time high assets under management, strong client activity, and improved operating leverage. Capital and liquidity positions remain robust, with reaffirmed growth and efficiency targets for the coming years.Original document: Julius Baer Gru…
A merger will create Europe's largest independent oil and gas producer, combining high-quality assets and expanding market reach. BlueNord shareholders receive new shares and cash, with the deal expected to deliver significant synergies, increased dividends, and long-term value.Original document: B…
Net profit more than doubled year-over-year to CHF 519.4 million, driven by higher operating income and strong net commission and fee income. Assets under management rose to CHF 458.5 billion, supported by positive market performance and net inflows.Original document: Julius Baer Gruppe AG [BAER] I…
The combination will create Europe's largest independent oil and gas producer, targeting ~450 kboepd and delivering significant financial synergies, enhanced cash generation, and long-term dividend capacity. The deal is expected to close by end-2026, pending approvals.Original document: Var Energi…
A major combination with BlueNord will create Europe's largest independent oil and gas producer, raising long-term production targets and dividend capacity. The deal brings significant synergies, a robust resource base, and maintains strong financial discipline.Original document: Var Energi ASA [VA…
Organic sales grew 4.3% despite volume and currency headwinds, with EBIT margin at 11.2% and net income margin at 8.2%. Strong growth in North America and Rest of the World offset weaker Europe, while guidance for 2026 is reaffirmed at 4-6% organic growth.Original document: Chocoladefabriken Lindt…
Sales and EBITDA were stable year-over-year, with margin improvements and strong cash flow. Perlen Packaging saw robust demand and innovation, while Zeochem faced mixed results. The group raised its dividend payout ratio and expects slightly higher sales and EBITDA for 2026.Original document: CPH G…
Net sales for H1 2026 were CHF 2,332.1 million, with net income at CHF 191.7 million, both nearly flat year-over-year. A CHF 1 billion share buyback was launched, and a one-time U.S. tariff refund boosted other income. Seasonality continues to impact profitability and cash flow.Original document: C…
Organic sales grew 4.3% to CHF 2.33 billion, with strong double-digit growth in North America and Rest of the World, while Europe declined. EBIT margin improved to 11.2%, and free cash flow turned positive. Full-year guidance is confirmed, with targeted actions for volume recovery.Original document…
Q2 2026 saw 11% reported and 6% organic sales growth, with strong Prosthetics & Neuro Orthotics performance and improved EBITDA margin at 22%. Net profit rose 39% year-over-year, and free cash flow was robust. Guidance for 2026 organic sales growth narrowed to 5-7%.Original document: Embla Medical…
Net operating income and income from property management rose sharply year-over-year, driven by acquisitions, project completions, and higher rents. Occupancy reached 95%, and the property portfolio expanded to SEK 17,976 million. Robust liquidity and strong demand for logistics and light industria…
Record Q2 2026 results with USD 3.7 billion in income and USD 839 million net profit, driven by high realized prices and operational efficiency. Announced BlueNord combination, reduced leverage to 0.4x, and maintained strong liquidity. Production guidance and dividend outlook remain robust.Original…
Q2 2026 saw 11% reported and 6% organic sales growth, with strong Prosthetics & Neuro Orthotics performance and improved profitability. Net profit rose 39% year-over-year, and guidance for full-year organic sales growth was narrowed to 5-7% with EBITDA margin maintained at 20-22%.Original document…
Q2 2026 saw 16% revenue growth and 28% EBITA growth, with strong margins led by Assistive Tech and MedTech. The Biopsafe acquisition expanded MedTech, while Specialty Pharma improved margins and sales. Net debt/EBITDA remains low, supporting further M&A.Original document: MedCap AB [MCAP] Slides Re…
AMC Entertainment (AMC) stock is heading toward its fourth straight month of gains as investors digest record-setting second quarter (Q2) earnings, with CEO Adam Aron outlining six strategic moves that helped the theater chain deliver its strongest performance in more than a century while rebuildin…
Sales and EBITDA remained stable in H1 2026, with improved margins and strong cash flow. Perlen Packaging outperformed, while Zeochem faced margin pressure. The group raised its dividend payout ratio and expects slightly higher full-year sales and EBITDA.Original document: CPH Group AG Class A [CPH…
H1 2026 saw stable sales and improved gross profit, but lower EBITDA and net result year-over-year. Perlen Packaging outperformed with higher organic growth, while Zeochem faced margin pressure. Outlook for 2026 is cautiously optimistic, with sales and EBITDA expected to rise slightly.Original docu…
Aims to Raise Capital to Fund Global Clinical Studies for LNP7457 (PRMT5) & LNP8701 (SOS1)MUMBAI, India and NAPLES, Fla., July 21, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE:LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic s…
Q1 FY27 saw 57% YoY income growth, margin expansion, and a third consecutive profitable quarter. AI-driven platforms scaled across segments, and the Housing.com acquisition is set to enhance the integrated PropTech ecosystem.Original document: Aurum Proptech Limited [AURUM] Slides Release — Jul. 21…
Kontron AG/ Key word(s): Incoming OrdersKontron secures a new European customer for 5G automotive modules manufactured in Germany21.07.2026 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Kontron’s 5G technology into a leading European OEM’s vehicle platform –…
